Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term analogs &. Found 11 abstracts

Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology 13 (2): 150-158 Feb 2006. 2006 Feb;13(2):150-8.
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct;8(10):3100-4.
Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001 Jan;19(1):89-92.
Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol. 2001 Aug;48(2):169-76.
Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr;91(7):1256-63.
Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am. 2001 Jun;15(3):525-45.
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001 Nov 15;92(10):2639-47.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term analogs &

analogs & derivatives administration & dosage Male adverse effects Female drug therapy Aged therapeutic use Adult adverse effects Human pathology Antineoplastic Combined Chemotherapy Protocols Middle Aged US Gov't Support-PHS 80 and over Aged metabolism Antineoplastic Antimetabolites Drug Administration Schedule Deoxycytidine pharmacokinetics Survival Analysis Treatment Outcome Middle Age antagonists & inhibitors Maximum Tolerated Dose Neoplasm Drug Resistance Paclitaxel Drug Dose-Response Relationship mortality Multicenter Studies Carboplatin Adjuvant Chemotherapy Non-US Gov't Support chemically induced Neoplasm Proteins Cohort Studies Colorectal Neoplasms pharmacology Enzyme Inhibitors Pancreatic Neoplasms Disease Progression surgery Neoplasms Neutropenia therapy Tissue Distribution genetics analogs & derivatives Kidney Neoplasms Prognosis administration & US Gov't Support-Non-PHS Fluorouracil Phytogenic Antineoplastic Agents Xenograft Model Antitumor Assays Cultured Tumor Cells Dexamethasone Antineoplastic Agents Ovarian Neoplasms Apoptosis Intravenous Infusions Patient Selection immunology Thymidylate Synthase Poly I-C Proto-Oncogene Proteins Uracil radiotherapy Lymphoma Lung Neoplasms bcl-2 Genes Folic Acid Isoquinolines Mutation Glioma drug Alanine Transaminase Risk Factors Topoisomerase I Inhibitors GABA-A Receptors Phase I Clinical Trials CA-19-9 Antigen Interferon Inducers Camptothecin Rats blood toxicity Drug Delivery Systems Cisplatin Antisense Oligodeoxyribonucleotides Polylysine Leucovorin Hydrocortisone Oxidoreductases Phosphodiesterase Inhibitors Polyglutamic Acid Local Neoplasm Recurrence Fallopian Tube Neoplasms Carcinoma Protein Kinase Inhibitors Conformal Radiotherapy Epothilones Biological Tumor Markers Benzimidazoles Tubulin Signal Transduction Peritoneal Neoplasms Etoposide Aspartate Aminotransferases Neoplasm Staging Vomiting Survival Rate Non-Small-Cell Lung Carcinoma Nude Rats Post-Translational Protein Processing Nausea Adjuvant Radiotherapy use Half-Life dosage Phase II Clinical Trials Safety Early Termination of Clinical Trials Proto-Oncogene Proteins c-bcl-2 Prostatic Neoplasms Pilot Projects Drug Interactions Estramustine Palliative Care ras Proteins Thrombocytopenia Severity of Illness Index Sprague-Dawley Rats drug effects therapeutic Mitoxantrone Feasibility Studies Mitosis Radiotherapy Dosage Brain Neoplasms methods Oral Administration Adenocarcinoma Animal Microtubules Sulindac Neoadjuvant Therapy
Last updated on Wednesday, February 05, 2020